Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada
Kanker Payudara HR+/HER2-
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Ahluwalia, A., Jones, M. K., Matysiak-Budnik, T., & Tarnawski, A. S. (2014). VEGF and colon cancer growth beyond angiogenesis: Does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism? *Current Pharmaceutical Design, 20*(7), 1041–1044.

Ali, M., Mishra, D., & Singh, R. P. (2024). Cancer pathways targeted by berberine: Role of microRNAs. *Current Medicinal Chemistry*.

Asai, S., Goto, Y., Tanigawa, K., Tomioka, Y., Kato, M., Mizuno, K., Sakamoto, S., & Seki, N. (2023). MiR-15b-5p inhibits castration-resistant growth of prostate cancer cells by targeting the muscarinic cholinergic receptor CHRM3. FEBS Letters, 597(8), 1164-1175.

Bae, S. H., Hwang, T., & Han, M. R. (2023). Unraveling the hypoxia modulating potential of VEGF family genes in pan-cancer. *Genomics & Informatics, 21*(4), e44. doi:10.5808/gi.23061.

Bahadoran, E., Babaei, A., Ranji, R., & Ebadi, H. (2025). The role of miR-429 in cancer: From biogenesis, signaling pathways, interactions with long non-coding RNAs, and function to therapeutic application. *Critical Reviews in Oncology/Hematology, 175*, 105007.

Cai, Y., Yang, Y., Zhang, X., Ma, Q., & Li, M. (2022). TRPM2-AS promotes the malignancy of osteosarcoma cells by targeting miR-15b-5p/PPMID axis. Cell Cycle, 21(8), 835-850.

Castaño, I. M., Curtin, C. M., Shaw, G., Murphy, K. D., Duffy, T. J., & O'Brien, F. J. (2015). A novel collagen-nanohydroxyapatite microRNA-activated scaffold for tissue engineering applications capable of efficient delivery of both miR-mimics and antagomiRs to human mesenchymal stem cells.[1] *Journal of Controlled Release, 200*, 42–51.

Chakrabortty, A., Patton, D. J., Smith, B. F., & Agarwal, P. (2023). miRNAs: Potential as biomarkers and therapeutic targets for cancer.[2] *Genes (Basel), 14*(7), 1431.

UNIVERSITAS GADJAH MADA
Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada Kanker Payudara HR+/HER2-
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Chan, L. S., Yue, P. Y. K., Wong, Y. Y., & Wong, R. N. S. (2013). MicroRNA-15b contributes to ginsenoside-Rg1-induced angiogenesis through increased expression of VEGFR-2.[3] *Biochemical Pharmacology, 86*(3), 392–400.

Chen, H., & Tian, Y. (2016). MiR-15a-5p regulates viability and matrix degradation of human osteoarthritis chondrocytes via targeting VEGFA.[4] *BioScience Trends, 10*(6), 482–488.

Cuzziol, C. I., Castanhole-Nunes, M. M. U., Pavarino, É. C., & Goloni-Bertollo, E. M. (2020). MicroRNAs as regulators of VEGFA and NFE2L2 in cancer. *Gene, 753*, 144798.

Di Meo, A., Bartlett, J., Cheng, Y., Coleman, I. M., & Nelson, P. S. (2017). Liquid biopsy: A step forward towards precision medicine in urologic malignancies. *Molecular Cancer, 16*(1), 80.

Doğanlar, O., Doğanlar, Z. B., Delen, E., & Doğan, A. (2021). The role of melatonin in angio-miR-associated inhibition of tumorigenesis and invasion in human glioblastoma tumour spheroids. *Tissue and Cell, 72*, 101561.

Drakaki, A., & Iliopoulos, D. (2009). MicroRNA gene networks in oncogenesis. *Current Genomics, 10*(1), 35–41.

Drury, R., Verghese, E. T., & Hughes, T. A. (2012). The roles of microRNAs in sarcomas. *The Journal of Pathology, 227*(3), 275–285.

Duan, R., Pak, C., & Jin, P. (2007). Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Human Molecular Genetics, 16(9), 1124-1131.

Esakov, E. L., Hale, J., Richards, E. G., Torre-Healy, L., Gullapalli, K., Trivedi, D., Souchek, J., Bakin, A. V., Butt, T. R., & Kulkarni, P. (2019). Therapeutic strategies to induce ERα in luminal breast cancer to enhance tamoxifen efficacy. *Endocrine-Related Cancer, 26*(8), 689–698.

Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan UGM. (2023). *Laporan data registrasi kanker berbasis rumah sakit Dr. Sardjito FKKMK UGM: RKBR Desember 2023*. Diperoleh 17 Maret 2025, dari https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-desember-2023/

Felekkis, K., & Papaneophytou, C. (2024). The circulating biomarkers league: Combining miRNAs with cell-free DNAs and proteins. *International Journal of Molecular Sciences, 25*(2), 521.

UNIVERSITAS
GADJAH MADA
**Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada
Kanker Payudara HR+/HER2-**
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Ferracin, M., Veronese, A., & Negrini, M. (2010). Micromarkers: MiRNAs in cancer diagnosis and prognosis. *Expert Review of Molecular Diagnostics, 10*(3), 297–308.

Firdi, N. P., Sardjono, T. A., & Hikmah, N. F. (2022). Using pectoral muscle removers in mammographic image process to improve accuracy in breast cancer.[5] *Journal of Biomimetics, Biomaterials and Biomedical Engineering, 55*, 131-142.

Gaál, Z. (2024). Role of microRNAs in immune regulation with translational and clinical applications. *International Journal of Molecular Sciences, 25*(3), 1559.

Gambari, R. (2015). Delivery and biological activity of therapeutic miRNAs and miRNA modifiers. Dalam *MicroRNA in Regenerative Medicine* (hlm. 49–66).

Geindreau, M., Ghiringhelli, F., & Bruchard, M. (2021). Vascular endothelial growth factor, a key modulator of the anti-tumor immune response.[6] *International Journal of Molecular Sciences, 22*(17), 9224.

Ghafouri-Fard, S., Khoshbakht, T., Hussen, B. M., Jamal, H. H., Taheri, M., & Hajiesmaeili, M. (2022). A comprehensive review on function of miR-15b-5p in malignant and non-malignant disorders. *Frontiers in Oncology, 12*, 891969.

Harnprasopwat, R., Ha, D., Toyoshima, T., Lodish, H., Tojo, A., & Kotani, A. (2010). Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126. Biochemical and Biophysical Research Communications, 399(2), 117-122.

He, W., Turkeshi, A., Li, X., & Zhang, H. (2020). Progress in systemic co-delivery of microRNAs and chemotherapeutics for cancer treatment by using lipid-based nanoparticles. *Therapeutic Delivery, 11*(5), 283–297.

Holjencin, C., & Jakymiw, A. (2022). MicroRNAs and their big therapeutic impacts: Delivery strategies for cancer intervention. *Cells, 11*(15), 2366.

Höller, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023). Diagnostic and prognostic biomarkers of luminal breast cancer: Where are we now? *Breast Cancer: Targets and Therapy, 15*, 525–540.

Hua, Z., Lv, Q., Ye, W., Wong, C. K. A., Cai, G., Gu, D., Ji, Y., Zhao, C., Wang, J., Yang, B. B., & Zhang, Y. (2006). MiRNA-directed regulation of VEGF and

UNIVERSITAS
GADJAH MADA
**Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada
Kanker Payudara HR+/HER2-**
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

other angiogenic factors under hypoxia. *PLoS ONE, 1*(1), e116. doi:10.1371/journal.pone.0000116.

Hutajulu, S. H., Prabandari, Y. S., Bintoro, B. S., Wiranata, J. A., Widiastuti, M., Suryani, N. D., Arguni, E., & Allsop, M. J. (2022). Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. *PLoS ONE, 17*(1), e0262468.

Intriago-Baldeón, D. P., Pérez-Coral, E. S., Armas Samaniego, M. I., Romero, V. I., Pozo Palacios, J. C., & Bigoni-Ordóñez, G. D. (2025). Decoding Breast Cancer: Emerging Molecular Biomarkers and Novel Therapeutic Targets for Precision Medicine. *International Journal of Molecular Sciences*, *27*(1), 138.

Jia, X., Huang, J., Wu, B., Li, C., Chen, J., Zhou, J., & Li, Y. (2021). A competitive endogenous RNA network based on differentially expressed lncRNA in lipopolysaccharide-induced acute lung injury in mice.[7] *Frontiers in Genetics, 12*, 721018.

Kang, Y., Li, H., Liu, Y., & Li, Z. (2024). Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors. *Journal of Cancer Research and Clinical Oncology, 150*, 221. doi:10.1007/s00432-024-05714-5.

Karimi, L., Mansoori, B., Shanebandi, D., & Baradaran, B. (2017). Function of microRNA-143 in different signal pathways in cancer: New insights into cancer therapy. *Biomedicine and Pharmacotherapy, 91*, 337–344.

Kim, R. G., Kim, E. K., Kim, H. A., Koh, J. S., Kim, M. S., Kim, K. I., Park, B. W., Lee, K. S., & Noh, W. C. (2011). Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience. *European Journal of Surgical Oncology (EJSO), 37*(7), 629-634.

Király, J., Szabó, E., Fodor, P., Vass, A., Choudhury, M., Gesztelyi, R., Szász, C., Flaskó, T., Dobos, N., Zsebik, B., Steli, Á. J., Halmos, G., & Szabó, Z. (2024). Expression of hsa-miRNA-15b, -99b, -181a and Their Relationship to Angiogenesis in Renal Cell Carcinoma. *Biomedicines*, *12*(7), 1441. https://doi.org/10.3390/biomedicines12071441

Kourea, H. P., Dimitrakopoulos, F.-I., Koliou, G.-A., & Fountzilas, G. (2022). Clinical significance of major angiogenesis-related effectors in patients with

UNIVERSITAS
GADJAH MADA
**Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada
Kanker Payudara HR+/HER2-**
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

metastatic breast cancer treated with trastuzumab-based regimens. *Cancer Research and Treatment, 54*(4), 1006–1018.

Koutras, A., Kotoula, V., & Fountzilas, G. (2015). Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. *Pharmacogenomics, 16*(1), 79–94.

Kovacs, B., Lumayag, S., Cowan, C., & Xu, S. (2011). microRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats.[8] *Investigative Ophthalmology & Visual Science, 52*(7), 4402–4409.

Kurniawan, B. N., Ferianto, D., & Pieter Jr, J. (2022). Evaluation of breast cancer metastasis and mortality rates based on molecular subtype: A description study. *Breast Disease, 41*(1), 427-432.[9]

Larasati, A., Utama, M. S., & Kusumadjati, A. (2022). Profile of breast cancer patients with radiotherapy in Hasan Sadikin Hospital Bandung. *Indonesian Journal of Cancer, 16*(3), 142.

Lei, H., Fu, J., Gu, W., Qiao, H., Guo, H., Chen, Z., ... & Chen, T. (2026). Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention. *MedComm*, *7*(1), e70560.

Li, H.-M., Wan, X.-Y., Zhao, J.-Y., Li, S., Zhao, J.-Y., Li, Y., Zhao, S., Wu, B., & Zeng, W. (2023). Promising novel biomarkers and therapy targets: The application of cell-free seminal nucleotides in male reproduction research. *Translational Research, 254*, 1–13.

Li, J., Wang, Z., & Shao, Z. (2019). Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. *Cancer Medicine, 8*(7), 3248-3266.

Li, P. F., Chen, S. C., Xia, T., & Guo, J. M. (2014). Non-coding RNAs and gastric cancer. *World Journal of Gastroenterology, 20*(18), 5411–5419.

Li, X., Li, X.-Q., & Huang, S.-A. (2007). MicroRNA profiles and initiation, diagnosis and treatment of cancers in digestive organs. *World Chinese Journal of Digestology, 15*(25), 2671–2675.

Li, Z., Tian, J. M., Chu, Y., Zhu, H. Y., Wang, J. J., & Huang, J. (2023). Long non-coding RNA PVTI (PVT1) affects the expression of CCND1 and promotes doxorubicin resistance in osteosarcoma cells. Journal of Bone Oncology, 43, 100512.

UNIVERSITAS
GADJAH MADA
**Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada
Kanker Payudara HR+/HER2-**
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Liu, L., Liu, C., & Huang, Q. (2012). MicroRNA and tumor immunity. *Chinese Journal of Clinical Oncology, 39*(3), 151–155.

Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón-Lagos, M. (2020). Resistance and overcoming resistance in breast cancer. *Breast Cancer: Targets and Therapy, 12*, 211–229.

Ma, B., Wang, S., Wu, W., Shan, P., Chen, Y., Meng, J., Xing, L., Yun, J., Hao, L., Wang, X., Li, S., & Guo, Y. (2023). Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research. Biomedicine & Pharmacotherapy, 162, 114672.

Ma, H., & Zhao, J. (2023). Relationship between micro ribonucleic acid-15b and vascular endothelial growth factor and related inflammatory factors in peripheral blood of diabetic retinopathy patients. *Recent Advances in Ophthalmology*.

Ma, Y. P., Yang, Y., Zhang, S., Yang, J.-H., Chen, J.-P., & Zhang, Y. (2010). Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP.[10] *Journal of Experimental and Clinical Cancer Research, 29*, 85.

Mabeta, P., & Steenkamp, V. (2022). The VEGF/VEGFR axis revisited: Implications for cancer therapy. *International Journal of Molecular Sciences, 23*(24), 15585. doi:10.3390/ijms232415585.

Mäenpää, N., Tiainen, L., Hämäläinen, M., & Jukkola, A. (2024). Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer. *BMC Cancer, 24*(1), 173.

Mahaki, H., Nobari, S., Tanzadehpanah, H., & Sheykhhasan, M. (2025). Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights. *Biomedicine and Pharmacotherapy, 175*, 114317.

Maqsood, Q., Khan, M. U., Fatima, T., Khalid, S., & Malik, Z. I. (2025). Recent insights into breast cancer: molecular Pathways, epigenetic Regulation, and emerging targeted therapies. *Breast Cancer: Basic and Clinical Research*, *19*, 11782234251355663.

Marra, A., Trapani, D., Ferraro, E., & Curigliano, G. (2023). Mechanisms of endocrine resistance in hormone receptor-positive breast cancer. *Cancer Treatment and Research, 186*, 1-21.

UNIVERSITAS
GADJAH MADA
**Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada
Kanker Payudara HR+/HER2-**
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Martinez-Gutierrez, A. D., Catalan, O. M., Vázquez-Romo, R., López-Urrutia, E., & Castellanos-Juárez, J. C. (2019). MiRNA profile obtained by next-generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments.[11] *International Journal of Molecular Medicine, 43*(3), 1251–1263.

Martínez-Rodríguez, A., Fuentes-Antrás, J., Lorca, V., Santaballa, A., Palacios, J., & Peiró, G. (2024). Molecular profiling of endocrine resistance in HR+/HER2- metastatic breast cancer: Insights from extracellular vesicles-derived DNA and ctDNA in liquid biopsies.[12] *International Journal of Molecular Sciences, 25*(12), 6497.

Mattick, J. S., Amaral, P. P., Carninci, P., Carpenter, S., Chang, H. Y., Chen, L. L., Chen, R., Dean, C., Dinger, M. E., Fitzgerald, K. A., ... Wu, M. (2023). Long non-coding RNAs: Definitions, functions, challenges and recommendations. Nature Reviews Molecular Cell Biology, 24(6), 430-447.

Maurer, C., Martel, S., Zardavas, D., & Ignatiadis, M. (2017). New agents for endocrine resistance in breast cancer. *The Breast, 33*, 93-103.

Migliaccio, I., Leo, A., Galardi, F., Gaggelli, C., Salvianti, F., & Malorni, L. (2021). Circulating biomarkers of cdk4/6 inhibitors response in hormone receptor positive and her2 negative breast cancer. *Cancers, 13*(11), 2539.

Moldovan, L., Batte, K. E., Trgovcich, J., Wisler, J., Marsh, C. B., & Piper, M. (2014). Methodological challenges in utilizing miRNAs as circulating biomarkers. *Journal of Cellular and Molecular Medicine, 18*(3), 371–390.

Momenimovahed, Z., & Salehiniya, H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast cancer: targets and therapy*, 151-164.

Munzone, E., & Colleoni, M. (2018). Optimal management of luminal breast cancer: How much endocrine therapy is long enough? *Therapeutic Advances in Medical Oncology, 10*, 1758835918781734.

Mytsyk, Y., Dosenko, V., Skrzypczyk, M. A., Drelich-Zbroja, A., & Zajączkowski, T. (2018). Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma. *Central European Journal of Urology, 71*(3), 295–303.

Nabweyambo, S., Kanyerezi, S., Petterson, J.HO. *et al.* No association of a Vascular endothelial growth factor A (VEGFA) gene polymorphism with

UNIVERSITAS GADJAH MADA
Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada Kanker Payudara HR+/HER2-
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

pre-eclampsia among pregnant women in Uganda. *BMC Genomics* **24**, 132 (2023).

Ng, B., Puspitaningtyas, H., Wiranata, J. A., Hutajulu, S. H., Widodo, I., Anggorowati, N., Utoro, T., & Sripan, P. (2023).[13] Breast cancer incidence in Yogyakarta, Indonesia from 2008–2019: A cross-sectional study using trend analysis and geographical information system. *PLoS ONE, 18*(7), e0288073.

Nikitina, E. G., Urazova, L. N., & Stegny, V. N. (2012). MicroRNAs and human cancer. *Experimental Oncology, 34*(1), 2–8.

O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Frontiers in Endocrinology, 9*, 402.

Octaviani, T. L., & Rustam, D. Z. (2019, November). Random forest for breast cancer prediction. Dalam *AIP Conference Proceedings* (Jil. 2168, No. 1, hlm. 020092). AIP Publishing.

Osborne, A., Adnani, Q. E. S., & Ahinkorah, B. O. (2025). Breast cancer incidence in Indonesia: A sex-disaggregated analysis using WHO health equity assessment toolkit data. *BMC Cancer, 25*(1), 1-8.

Ozawa, P. M. M., Jucoski, T. S., Vieira, E., Urban, C. A., & de Almeida, L. M. (2020). Liquid biopsy for breast cancer using extracellular vesicles and cell-free microRNAs as biomarkers. *Translational Research, 223*, 40–53.

Panwalkar, P., Khire, A., Shirsat, N. (2022). Validation of microRNA Target Genes Using Luciferase Reporter assay and Western Blot Analysis. In: Dey, A., Malhotra, A., Garg, N. (eds) Medulloblastoma. Methods in Molecular Biology, vol 2423. Humana, New York, NY

Paskeh, M. D. A., Mirzaei, S., Orouei, S., & Samarghandian, S. (2021). Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers. *International Journal of Biological Macromolecules, 189*, 539–550.

Patil, K., Joseph, S., Shah, J., & Mukherjee, S. (2022).[14] An integrated in silico analysis highlighted angiogenesis regulating miRNA-mRNA network in PCOS pathophysiology.[15] *Journal of Assisted Reproduction and Genetics, 39*(4), 823–838.

UNIVERSITAS
GADJAH MADA
**Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada
Kanker Payudara HR+/HER2-**
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Pellegrino, B., Hlavata, Z., Migali, C., De Silva, P., Aiello, M., Willard-Gallo, K., & Scomadi, I. (2021). Luminal breast cancer: Risk of recurrence and tumor-associated immune suppression. *Molecular Diagnosis & Therapy, 25*(4), 409–424.

Polidorio, N., Montagna, G., Sevilimedu, V., Le, T., & Morrow, M. (2024). Do HER2-low tumors have a distinct clinicopathologic phenotype? *Annals of Surgical Oncology, 31*(4), 2231-2243.

Raimondi, L., Amodio, N., di Martino, M. T., Altomare, E., Leotta, M., & Carina, V. (2014). Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity. *Oncotarget, 5*(15), 7382–7396.

Rhodes, A., & Yip, C. (2011). Comparison of breast cancer in Indonesia and Malaysia–A clinico-pathological study between Dharmais cancer centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. *Asian Pacific Journal of Cancer Prevention, 12*(11), 2943-2946.

Richman, J., Schuster, G., Buus, R., Lopez-Knowles, E., & Dowsett, M. (2024). Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients. *Breast Cancer Research and Treatment, 206*(1), 195–205.

Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nature Reviews Drug Discovery, 16*(3), 203–221.

Sahranavardfard, P., Madjd, Z., Razavi, A. E., Asadi-Lari, M., & Roudi, R. (2021). An integrative analysis of the micro-RNAs contributing in stemness, metastasis and B-Raf pathways in malignant melanoma and melanoma stem cell. *Cell Journal, 23*(3), 301–312.

Sayyed, A. A., Gondaliya, P., Bhat, P., & Alex, A. T. (2022). Role of miRNAs in cancer diagnostics and therapy: A recent update. *Current Pharmaceutical Design, 28*(30), 2480–2493.

Setyarini, A. I., & Rahaningtyas, I. (2018). The socialization of breast cancer early-detection screening for productive women in society health center of Dono, Tulungagung District, Indonesia. *International Journal of Scientific and Technology Research, 7*(8), 130–131.

Seyhan, A. A. (2024). Trials and tribulations of microRNA therapeutics. *International Journal of Molecular Sciences, 25*(3), 1541.

UNIVERSITAS GADJAH MADA
Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada Kanker Payudara HR+/HER2-
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Shahab, A.Z.A. (2025). Profil Ekspresi Plasma Circulating miRNA sebagai Kandidat Biomarker Prediktor Metastasis Tulang pada Pasien Kanker Payudara HR+/HER2-. Tesis.

Shahidsales, S., Joudi, M., Mirsadraee, M., Avan, A., AHMADI, S. S., & GHAVAMNASIRI, M. R. (2018). Clinicopathologic features and survival of breast cancer subtypes in northeast Iran.

Shang, C., & Xu, D. (2022). Epidemiology of Breast Cancer. *Oncologie (Tech Science Press)*, *24*(4).

Sharma P, Chida K, Wu R, et al. *VEGFA* Gene Expression in Breast Cancer Is Associated With Worse Prognosis, but Better Response to Chemotherapy and Immunotherapy. *World J Oncol*. 2025;16(1):120-130. doi:10.14740/wjon1993

Shen, L.-S., Jin, X.-Y., Wang, X.-M., & Wang, J.-H. (2020). Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. *Chinese Medical Journal, 133*(10), 1205-1214.

Shi, Z., Kuai, M., Li, B., Akowuah, C. F., Wang, Z., Pan, Y., Tang, M., Yang, X., & Lü, P. (2025). The role of VEGF in cancer angiogenesis and tumorigenesis: Insights for anti-VEGF therapy. *Cytokine, 189*, 156908. doi:10.1016/j.cyto.2025.156908.

Shin, D., Yoo, J.-O., Jeong, J.-H., & Han, Y.-H. (2025). MiR-5586-5p suppresses hypoxia-induced angiogenesis through multiple targeting of HIF-1α, HBEGF and ADAM17 in breast cancer.[16] *Anticancer Research, 45*(2), 785–796.

Srinivas, C., Ramaiah, M. J., Lavanya, A., Sotheeswaran, S., & Murali, Y. K. (2015). Novel etoposide analogue modulates expression of angiogenesis associated microRNAs and regulates cell proliferation by targeting STAT3 in breast cancer.[17] *PLoS ONE, 10*(5), e0125176.

Sun, P., Liu, D. Z., Jickling, G. C., & Sharp, F. R. (2018). MicroRNA-based therapeutics in central nervous system injuries. *Journal of Cerebral Blood Flow & Metabolism, 38*(7), 1125–1146.

Sun, W., Lan, J., Chen, L., Qiu, J., Luo, Z., Li, M., Wang, J., Zhao, J., Zhang, T., Long, X., Chai, J., Yan, Z., Guo, Z., & Gun, S. (2017). A mutation in

UNIVERSITAS GADJAH MADA
Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada Kanker Payudara HR+/HER2-
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

porcine pre-miR-15b alters the biogenesis of miR-15b\16-1 cluster and strand selection of miR-15b. *PLoS One*, 12(5), e0178045.

Tang, J., Ahmad, A., & Sarkar, F. H. (2012). The role of microRNAs in breast cancer migration, invasion and metastasis. *International Journal of Molecular Sciences, 13*(10), 13414-13437.

Tobelem, G. (2007). VEGF: A key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. *Targeted Oncology, 2*(3), 131–139.

Tufail, M., Cui, J., & Wu, C. (2022). Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches. *American Journal of Cancer Research, 12*(7), 2920–2949.

Turner, K. M., Yeo, S. K., Holm, T. M., Shaughnessy, E., & Guan, J. L. (2021).[18] Heterogeneity within molecular subtypes of breast cancer. *American Journal of Physiology-Cell Physiology, 321*(2), C343–C354.

Valle-Solís, A. E., Miranda-Aguirre, A. P., Mora-Pérez, J., Pineda-Juárez, J. A., Gallardo-Valencia, L. E., Santana, L., Cervantes-Sánchez, G., & Cárdenas-Cárdenas, E. (2019). Breast cancer survival by immunohistochemistry-determined subtype: A retrospective study. *Gaceta Médica de México, 155*(Suppl 1), S39–S43.

Wang, F., Zu, Y., Zhu, S., Yang, Y., Huang, W., Xie, H., & Zu, Y. (2018). Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression. Biochemical and Biophysical Research Communications, 507, 231-235.

Wang, H., Yang, Q., Li, J., & Zhang, J. (2021). MicroRNA-15a-5p inhibits endometrial carcinoma proliferation, invasion and migration via downregulation of VEGFA and inhibition of the Wnt/β-catenin signaling pathway.[19] *Oncology Letters, 21*(3), 223.

Wang, L., Zhu, M.-J., Ren, A.-M., Tu, R.-Q., Wang, J., & Li, X.-Y. (2014). A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.[20] *PLoS ONE, 9*(5), e96472.

Wang, V., & Wu, W. (2009). MicroRNA-based therapeutics for cancer. *BioDrugs, 23*(1), 15–23.

UNIVERSITAS GADJAH MADA
Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada Kanker Payudara HR+/HER2-
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Wang, Y., Bai, H., Jiang, M., & Gong, Z. (2023). Emerging role of long non-coding RNA JPX in malignant processes. *Chinese Medical Journal, 136*(1), 66–74.

Wicik, Z., Czajka, P., Eyileten, C., & Postula, M. (2022). The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis. *Platelets, 33*(3), 362–370.

Winter, J., & Diederichs, S. (2011). MicroRNA biogenesis and cancer. Dalam J. M. Walker (Ed.), *Methods in Molecular Biology* (Jil. 676, hlm. 3–22). Humana Press.

World Health Organization. (2022). *Global Cancer Observatory: Indonesia fact sheet*. Diperoleh 17 Maret 2025, dari https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf

Wu, H., Wei, M., Li, Y., Feng, Y., Yang, J., & Liu, C. (2022). Research progress on the regulation mechanism of key signal pathways affecting the prognosis of glioma. *Frontiers in Molecular Neuroscience, 15*, 834769.

Xu, J., Zhang, J., Shan, F., Wen, J., & Wang, Y. (2019). SSTR5-AS1 functions as a ceRNA to regulate CA2 by sponging miR-15b-5p for the development and prognosis of HBV-related hepatocellular carcinoma. Molecular Medicine Reports, 20(6), 5021-5031.

Yan, T. T., Hong, J., & Fang, J. Y. (2014). Regulatory function of long non-coding RNAs in tumor metastasis. *Tumor, 34*(6), 579–585.

Yang, S. X., Steinberg, S. M., Nguyen, D., & Swain, S. M. (2011). p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.[21] *International Journal of Oncology, 38*(5), 1445–1453.

You, J. S., & Jones, P. A. (2012). Cancer genetics and epigenetics: Two sides of the same coin? *Cancer Cell, 22*(1), 9–20.

Zaheer, U., Faheem, M., Qadri, I., & Mathew, S. (2019). Expression profile of MicroRNA: An emerging hallmark of cancer. *Current Pharmaceutical Design, 25*(4), 359–372.

Zambelli, A., Gallerani, E., Garrone, O., Pedersini, R., Caremoli, E. R., Sagrada, P., Cazzaniga, M. E., & Aebi, S. (2023). Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2

UNIVERSITAS
GADJAH MADA
**Analisis Ekspresi hsa-miR-15b-5p sebagai Kandidat Biomarker dan Regulasinya terhadap VEGFA pada
Kanker Payudara HR+/HER2-**
Reza Adhi Pratama, Prof. dr. Sofia Mubarika Haryana, M.Med.Sc, Ph.D; Dr.rer.nat. dr. Dyah Laksmi Dewi M.Sc., Sp.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

negative (HER2-) early stage breast cancer: defining high risk of recurrence. *Critical Reviews in Oncology/Hematology, 191*, 104104.

Zhang, B., & Ye, Q. (2024). Linc00662 sponges miR-15b-5p to promote hypopharyngeal squamous cell carcinoma progression by facilitating cancer stem cell-like phenotypes. Journal of Cancer, 15(12), 3781.

Zhao, J., Huang, F., Xu, X., & Li, Q. (2024). Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer.[22] *Frontiers in Oncology, 14*, 1358604.

Zhao, T., Jin, Q., Kong, L., Liu, Y., Zhao, M., & Yang, P. (2022). microRNA-15b-5p shuttled by mesenchymal stem cell-derived extracellular vesicles protects podocytes from diabetic nephropathy via downregulation of VEGF/PDK4 axis.[23] *Journal of Bioenergetics and Biomembranes, 54*(2), 175–189.

Zhao, Y., Song, Y., Zhang, Y., & Zhang, W. (2023). Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer. *Molecular and Cellular Probes, 67*, 101906.

Zhou, Y., Fan, R. G., Qin, C. L., Jia, J., Wu, X. D., & Zha, W. Z. (2019). LncRNA-H19 activates CDC42/PAK1 pathway to promote cell proliferation, migration and invasion by targeting miR-15b in hepatocellular carcinoma. Genomics, 111(6), 1862-1872.

Zhu, L.-P., Zhou, J.-P., Zhang, J.-X., & Zhang, G.-G. (2017). MiR-15b-5p regulates collateral artery formation by targeting AKT3 (protein kinase B-3).[24] *Arteriosclerosis, Thrombosis, and Vascular Biology, 37*(7), 1332–1343.

Zhu, Z., Han, G., Huang, H., & Liang, W. (2021). Genome-wide discovery of MicroRNA biomarkers for cancer precision medicine. Dalam *RSC Detection Science*.

Zhuang, L. K., & Tong, J. H. (2011). MicroRNA and gene regulation in hematopoietic tumors. *Journal of Shanghai Jiaotong University (Medical Science), 31*(4), 399–403.